Taysha Gene Therapies, Inc. Common Stock (TSHA) is a publicly traded Healthcare sector company. As of May 21, 2026, TSHA trades at $5.48 with a market cap of $1.56B and a P/E ratio of -14.25. TSHA moved +5.69% today. Year to date, TSHA is +12.27%; over the trailing twelve months it is +87.37%. Its 52-week range spans $1.05 to $7.30. Analyst consensus is strong buy with an average price target of $12.10. Rallies surfaces TSHA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Taysha Gene Therapies, Inc. Common Stock (TSHA) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. TSHA moved +5.69% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $5.48 |
| Market Cap | $1.56B |
| P/E Ratio | -14.25 |
| EPS | $-0.38 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.30 |
| 52-Week Low | $1.05 |
| Volume | 2.24M |
| Avg Volume | 0 |
| Revenue (TTM) | $7.47M |
| Net Income | $-129.88M |
| Gross Margin | 0.00% |
10 analysts cover TSHA: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.10.